Please fill in the details for us to get in touch with you.


Dr. R S Khedar

Director- Internal Medicine & Critical Care, Medical Director

He is the director of Internal Medicine and Critical Care department.

  • Education & Experience
  • Special Interests
  • Awards & Honours
  • Publications


  • MBBS, University of Rajasthan.
  • MD, University of Rajasthan.
  • Senior Resident Cardiology, Sunderlal Jain Hospital, Delhi
  • Non Invasive Cardiology Certificate Course, AIIMS.

Work Experience

  • Director, Dept. of Internal Medicine Fortis Escorts Hospital Jaipur.
  • Additional Director, Dept. of Internal Medicine, Fortis Escorts Hospital, Jaipur.
  • Senior Consultant, Dept. of Internal Medicine,Fortis Escorts Hospital, Jaipur
  • Consultant, Dept. of Internal Medicine, Fortis Escorts Hospital, Jaipur
  • Junior Specialist Medicine, Dept. of Health and Family Welfare, Govt. of Rajasthan.
  • Head, Dept. of Medicine Cardiology (Govt. Deputation),V.S.S.S.Bhadra Dist. Hanumangarh, Raj.
  • Medical Officer, Dept. of Health & Family Welfare, Govt. of Rajasthan
  • Infectious Diseases
  • Critical Care work
  • Research- Preventive Medicine
  • Community Outreach Work
  • Hypertension
  • Lipid Dysfunction
  • API
  • Indian Academy of Echo Cardiography
  • Cardiology Society of India (CSI)
  • Faculty Diplomate of National Board (DNB)
  • Faculty member of IGNOU medical post graduate courses, Jaipur


  • Guillain Barre Syndrome; an unusual complication of Dengue fever; Scholar Journal of Medical Case Report 2014 2{3} 133-135
  • Gupta R, Khedar RS. Poor governance is leading to healthcare crisis in India. PROCOR 2010. E1-2
  • Gupta R, Sharma KK, Gupta A, Agrawal A, Mohan I, Gupta VP,Khedar RS, Guptha S. Persistent high prevalence of cardiovascular risk factors in the urban middle-class in India: Jaipur Heart Watch-5. J Association Physicians India. 2012; 60(3): 11-16
  • Sharma KK, Mathur M, Gupta R, Guptha S, Roy S,Khedar RS, Gupta N, Gupta R. Epidemiological study of cardio protective pharmacological agents use in stable coronary heart disease. Indian Heart J. 2013;250-255
  • Gupta R, Gupta N,Khedar RS. Smokeless tobacco and cardiovascular disease in low and middle income countries. Indian heart J. 2013; 65:369-377
  • Gupta R, Sharma KK, Ahuja S, Khedar RS. Overuse of non-evidence based pharmacotherapies in coronary heart disease. Indian J Public Health. 2013; 57:280-281
  • Ghanshani RV, Gupta R, Sood S, Joad SHK, Bansal A,Khedar RS. Epidemiology of infections in a medical ICU in India. Intensive care Med. Submitted.
  • Gupta R,Khedar RS. Hypertension management in primary care: focus on lifestyle and initial drug therapies. South Asian J Preventive Cardiology 2008; 11:185-199.
  • Gupta R, Sharma KK, Gupta A, Mohan I,Khedar RS, Guptha S. High prevalence of cardiovascular risk factors in the urban middle class in India: Jaipur Heart Watch-5. India Heart J 2011; 63:541-542
  • Gupta R, Agrawal A,Khedar RS, Porwal RK, Guptha S, Gupta VP. Increasing hypertension awareness and declining systolic blood pressure among urban subjects in India. Indian Heart J 2011: 63:551
  • Gupta R, Sharma KK, Gupta BK,Khedar RS, Deedwania PC. Education status related inequities in awareness, treatment and control of cardiovascular risk factors in India: Cross-sectional study. Global Heart. 2013
  • CRESCENDO Study: Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints & Outcomes. Study Identifier NCT00263042. Sponsor: Sanofi Aventis, USA. Principal Investigator: Prof Eric J Topol, Scripps Clinic, CA, USA
  • MARS study. Metoprolol and/or Amlodipine Trial in Mild Hypertension
  • LIFENOX Study. Enoxaparin for prevention of deep vein thrombosis in acutely ill medical patients. Sponsor: Sanofi Aventis, UK. Principal investigator: Prof Ajay K Kakkar, London, UK.
  • ASPIRE Study. Aspirin to Prevent Recurrent Venous Thromboembolism. Principal Investigator: T Brighton, Sydney, Australia.
  • TRILOGY ACS Study. Targeted Platelet Inhibition to clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes. Duke Clinical Research Institute, USA
  • UMPIRE Study. Evaluation of fixed dose combinations in secondary prevention of cardiovascular disease. Sponsor: European Union. Principal Investigator: Prof D Prabhakaran, New Delhi
  • STABILITY Study. Stabilisation of Atherosclerotic Plaque by Initiation of Darapladib Therapy. Phase III study. Sponsor: GlaxoSmithKline Inc, UK. Duke Clinical Research Institute, USA
  • SAVOR TIMI-53 Study. Assessment of vascular outcomes in type 2 diabetes. Phase III study. Sponsor: Astra Zeneca. TIMI Study Group, Harvard Medical School, USA
  • Lotus Clinical Research Academy P Ltd, Bangalore. Prospective registry of risk factors in premature CAD in Indians.
  • HOPE-3 Study. Heart Outcomes prevention Evaluation-3 Study. Principal Investigators: Prof Salim Yusuf, (Hamilton, Canada); Prof Prem Pais/Denis Xavier (Bangalore).
  • Astra Zeneca India. Epidemiological Study of anti-thrombotic drug use in patients after acute coronary syndrome (EpiCOR Asia Registry).
  • TIPS-3 study. The International Polycap Study-3. Evaluation of Polycap, low dose aspirin and Vitamin D supplementation in primary prevention. St John's Research Institute, Bangalore and population Health Research Institute, Hamilton, Canada.